Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight NCI to remain intact, but its finances are uncertain; FDA is spared big cuts

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

How is the enterprise of cancer research doing after the first 100 days of the Trump administration?

May 09, 2025

George Weiner: Cancer centers are special, as are site visits in CCSG review

The cancer center program of the NCI is a success that is admired not only within the NIH but worldwide. This is due, in large part, to the cancer center review process that has evolved and strengthened over the years.

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.

May 09, 2025

Vol.51 No.18

By Claire Marie Porter

Cancer Policy

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Over $180 million in NCI grants have been terminated between Feb. 28 and April 8, according to a systematic review published in JAMA May 8.

Bhattacharya cancels NIH all-hands meeting

In an interview with Science, NIH Director Jay Bhattacharya said that his time at the NIH has been a “tough period”—especially for him.

NIH to update policies and practices, halting subawards to foreign entities

In a statement issued on May 1, NIH said it’s immediately halting most new grant awards to foreign partners working in US-led research consortia.

May 09, 2025

Vol.51 No.18

By Claire Marie Porter

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight

NCI to remain intact, but its finances are uncertain; FDA is spared big cuts

YOU MAY BE INTERESTED IN

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

George Weiner: Cancer centers are special, as are site visits in CCSG review

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Bhattacharya cancels NIH all-hands meeting

NIH to update policies and practices, halting subawards to foreign entities

Renew today!

Subscriber content

Never miss an issue!

Login

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight

NCI to remain intact, but its finances are uncertain; FDA is spared big cuts

YOU MAY BE INTERESTED IN

Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit

George Weiner: Cancer centers are special, as are site visits in CCSG review

Cyber-iconoclast Vinay Prasad named head of FDA’s CBERAn oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Bhattacharya cancels NIH all-hands meeting

NIH to update policies and practices, halting subawards to foreign entities

Never miss an issue!

Login

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies